WO2014190030A1 - Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide - Google Patents

Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide Download PDF

Info

Publication number
WO2014190030A1
WO2014190030A1 PCT/US2014/038933 US2014038933W WO2014190030A1 WO 2014190030 A1 WO2014190030 A1 WO 2014190030A1 US 2014038933 W US2014038933 W US 2014038933W WO 2014190030 A1 WO2014190030 A1 WO 2014190030A1
Authority
WO
WIPO (PCT)
Prior art keywords
annexin
tin
administered
dota
radionuclide
Prior art date
Application number
PCT/US2014/038933
Other languages
French (fr)
Other versions
WO2014190030A8 (en
Inventor
Nigel R. STEVESON
Gilbert R. Gonzales
Original Assignee
Steveson Nigel R
Gonzales Gilbert R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steveson Nigel R, Gonzales Gilbert R filed Critical Steveson Nigel R
Priority to KR1020157036396A priority Critical patent/KR20160021789A/en
Priority to CN201480039998.4A priority patent/CN105658244A/en
Priority to EP14731119.5A priority patent/EP2999487A1/en
Priority to AU2014268593A priority patent/AU2014268593A1/en
Priority to US14/891,835 priority patent/US10286093B2/en
Priority to RU2015155001A priority patent/RU2015155001A/en
Priority to JP2016515042A priority patent/JP2016522832A/en
Priority to CA2913296A priority patent/CA2913296A1/en
Publication of WO2014190030A1 publication Critical patent/WO2014190030A1/en
Publication of WO2014190030A8 publication Critical patent/WO2014190030A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the beta amyloid is formed from microglia, which are the macrophages of the brain. Microglia have several important functions in the brain. However, the microglia can become hyperactive and, as a result, cause the production and build-up of beta amyloid in the brain, which subsequently causes cognitive deterioration. Generally, most of the beta amyloid is produced prior to any clinical detection of even mild cognitive impairment. By the time of diagnosis, up the 50% of the brain mass may have been lost. Thus, any treatment of Alzheimer's should occur prior to the onset of dementia and, preferably, much earlier.
  • the present invention is premised on the realization that the build-up of beta amyloid can be inhibited by destroying the aged hyperactive microglia.
  • Hyperactive microglia can be destroyed by binding a short range radioactive isotope only to the aged hyperactive microglia. This will cause a destruction of the aged hyperactive microglia by induction of apoptosis in these microglia, preventing them from participating in the cascade of events that produces beta amyloid.
  • the present invention utilizes tin- 117m as a radionuclide to attach to the hyperactive microglia, and in particular, tin-117m-annexin V.
  • a second dosage of tin-1 17m attached to annexin Al can be administered.
  • the annexin Al assists in repair of the blood brain barrier, and the tin-117m in turn destroys any hyperactive microglia and other inflammatory immune reactive cells associated with the deterioration of the blood-brain barrier.
  • Alzheimer's disease is treated by
  • tin-annexin V administering to a patient an amount of a tin-annexin V effective to induce apoptosis of hyperactive microglia cells.
  • the tin-1 17m annexin is preferably formed from no-carrier-added tin-1 17m.
  • tin-1 17m There are various methods to produce no-carrier added tin-1 17m.
  • One such method is disclosed in Stevenson U.S. Patent 8,257,681 , the disclosure of which is hereby incorporated by reference, although other methods could be employed in the present invention.
  • the tin-117-m is a unique radioisotope. Although it emits some gamma radiation, the primary source of the radiation is a conversion electron. The radiation from the conversion electron penetrates a set distance, 290 microns, and, therefore, does not damage cells any farther than 290 microns away from the tin atom.
  • Annexins are a class of molecule having the ability to bind with high affinity to membrane lipids in the presence of millimolar concentrations of calcium. There are several different annexins.
  • the term "annexin” includes native annexin purified from natural sources, such as human placenta or annexin molecules containing a native sequence produced through, for example, genetic engineering, or other means.
  • the term annexin unless otherwise specified, includes annexms as defined below derived from or produced by any source.
  • Modified annexin is a molecule with a native sequence of molecules altered in such a way without materially altering the membrane binding affinity of the annexin.
  • Such annexins can be produced by chemical, genetic engineering or recombinant techniques as known to those of ordinary skill in the art.
  • the modification can include a modification of the sequence through the addition of several amino acid residues and/or an addition/deletion of amino acids at a single site of the native or genetically engineered sequence.
  • the annexin can be modified at the N- terminus by addition of amino acid residues wherein at least one of its amino acids provide an accessible sulfhydryl group.
  • the accessible sulfhydryl group or groups may be utilized during conjugation or remain available for further conjugation.
  • modified annexin includes annexin multimers.
  • Annexin multimers are a combination of two or more monomeric modified annexin molecules of which the components of the multimer may be native, or recombinant, or in any combination thereof resulting in similar or improved membrane binding affinity over the monomeric annexin.
  • a multimer composed of up to 20 modified annexins is useful in the present invention.
  • One example of an annexin multimer is an annexin dimer, which can be composed of two modified annexins linked by disulfide bonds between accessible cysteine groups on the modified annexins.
  • the annexin dimer can also be produced directly as a fusion protein.
  • linking molecule is used to attach the tin-117m to the annexin.
  • linking molecule is l,4,7, 10-tetraazacyclododecane-l,4,7, 10-tetraacetic acid, or DOTA.
  • DOTA dihydroxybenzyl DOTA
  • Formation of this molecule is disclosed in U.S. Patent No. 8,283,167, the disclosure of which is hereby incorporated by reference.
  • annexin V is preferably used to bind and destroy hyperactive microglia through induction of apoptosis.
  • Annexin Al is used to repair the blood brain barrier.
  • Alzheimer's disease is treated by administering an effective dosage of tin- 1 17m annexin V generally linked together with DOTA.
  • the dosage utilized in the present invention will vary depending upon the mode of administration.
  • the tin- 1 17m annexin V in a suitable carrier, such as saline can be administered intra- arterially, intra-spinally, including in the lumbar, or intra-cisternally, intra-vascularly, or directly into the ventricle of the brain.
  • a suitable carrier such as saline
  • the systemic injected dosage can vary widely and can be from about 3 millicuries up to 50 millicuries, generally about 3 millicuries to about 20 millicuries or 5 to 10 millicuries.
  • the hyperactive microglia has exposed phosphatidyl serine to which the annexin naturally binds. This binds the tin-1 17m to the hyperactive microglia.
  • tin- 117m only has a therapeutic energy in the form of conversion electrons that travels 290 microns and that in low therapeutic doses (i.e., non-DNA fracturing doses or hormesis doses), when attached to the microglia the radiation will mainly affect interneuronal areas in the brain where aged microglia are located.
  • the timing of administration should be as early as possible, and can, in fact, occur prior to any clinical signs of Alzheimer's.
  • Administration of tin-1 17m annexin V is warranted as soon as there is any indication of beta amyloid build-up, tauprotein formation, or other potential changes associated with Alzheimer's disease Because the build-up of beta amyloid precedes clinical signs of Alzheimer's by years, certainly as soon as any clinical signs of Alzheimer's are detected, the composition of the present invention should be administered.
  • the tin-1 17m annexin V can be readmmistered. As the tin- 1 17 remains in the brain for extended periods of time, well in excess of 400 hours, one should wait at least one to two half lives before readministering the tin- 117m.
  • the tin- 1 17m annexin can be readministered two or more times, generally for the remainder of the patient's life at 3-month to 1-year intervals.
  • the tin-1 17m annexin Al can b readministered at the same intervals.
  • aminobenzyl DOTA annexin Al can be administered at the same approximate dosage as the tin annexin V.
  • the annexin Al will help repair the blood brain barrier, which is normally in disrepair in individuals with Alzheimer's, and the associated tin- 117m will induce apoptosis in aged hyperactive microglia present.
  • the tin- 117m- annexin Al complex can be administered at the same time as the tin- 117m-annexin V complex, but preferably, one should wait approximately one half of the half life of the tin (or 7 days), up to about two half lives (or 28 days) before administering the tin-117m-annexin Al, so that the tin- 1 17m-annexin Al does not interfere with the tin-117m annexin V crossing the blood brain barrier.
  • the tin- 1 17m-annexin-V can be used as a diagnostic tool to determine the presence of hyperactive microglia by administering the tin-1 17m-DOTA annexin V and imaging the brain.
  • the tin-117m emits gamma radiation, which can be detected by SPECT.
  • a compound such as Tc-99m annexin V can be utilized purely for diagnostic purposes. Greater than normal radiation detected in the brain is indicative of Alzheimer's disease even prior to cognitive impairment.
  • Alzheimer's disease can be detected and/or treated at a very early stage by destroying hyperactive microglia cells before massive build-up of beta amyloid and the associated loss of brain mass and cognitive ability.
  • the present invention allows for a method of detecting the hyperactive microglia at a very early stage, and provides a specific mode of attacking the hyperactive microglia. Because a relatively low dosage is required, a hormesis affect is achieved. Further, because of the short effective distance of the emitted radiation from the tin- 1 17m, only white matter is affected and the grey matter, or neurons of the brain, are not adversely impacted by the present therapy. This can be repeated as needed, as the compound has minimal, if any, deleterious effect. Further, the present invention provides the added benefit of being able to repair the blood brain barrier.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Psychology (AREA)
  • Physiology (AREA)

Abstract

Alzheimer's disease is treated by attacking hyperactive microglia preferably before excessive beta amyloid is built up by administering tin-117m-DOTA annexin V. This compound in low radioactive doses selectively binds to the aged hyperactive microglia and emits a conversion electron which effectively induces apoptosis in the hyperactive microglia. A follow-up treatment of tin-annexin Al can be administered to repair the blood brain barrier. The annexin Al assists in the repair of the blood-brain barrier and the associated tin-117m will induce apoptosis in aged hyperactive microglia associated with the blood brain barrier.

Description

DIAGNOSING AND TREATING ALZHEIMER'S DISEASE USING ANNEXINS WITH LABELED WITH A RADIONUCLIDE
PRIORITY CLAIM
[0001] This application is based on, and claims priority to, United States provisional patent application Serial No. 61/826,701, filed May 23, 2013, the disclosure of which is hereby incorporated by reference in its entirety as if fully set forth herein.
BACKGROUND OF THE INVENTION
[0002] There are various theories on the causes and development of Alzheimer's disease. But, it is very clear that it involves a build-up of beta amyloid with subsequent deterioration of cognitive ability.
[0003] The beta amyloid is formed from microglia, which are the macrophages of the brain. Microglia have several important functions in the brain. However, the microglia can become hyperactive and, as a result, cause the production and build-up of beta amyloid in the brain, which subsequently causes cognitive deterioration. Generally, most of the beta amyloid is produced prior to any clinical detection of even mild cognitive impairment. By the time of diagnosis, up the 50% of the brain mass may have been lost. Thus, any treatment of Alzheimer's should occur prior to the onset of dementia and, preferably, much earlier.
[0004] Further, as with most neurodegenerative diseases, there is also a deterioration of the blood brain barrier.
SUMMARY OF THE INVENTION
[0005] The present invention is premised on the realization that the build-up of beta amyloid can be inhibited by destroying the aged hyperactive microglia. Hyperactive microglia can be destroyed by binding a short range radioactive isotope only to the aged hyperactive microglia. This will cause a destruction of the aged hyperactive microglia by induction of apoptosis in these microglia, preventing them from participating in the cascade of events that produces beta amyloid. In particular, the present invention utilizes tin- 117m as a radionuclide to attach to the hyperactive microglia, and in particular, tin-117m-annexin V.
[0006] In a further embodiment of the present invention, a second dosage of tin-1 17m attached to annexin Al can be administered. The annexin Al assists in repair of the blood brain barrier, and the tin-117m in turn destroys any hyperactive microglia and other inflammatory immune reactive cells associated with the deterioration of the blood-brain barrier.
[0007] The objects and advantages of the present invention will be further
appreciated in light of the following detailed description.
DETAILED DESCRIPTION
[0008] According to the present invention, Alzheimer's disease is treated by
administering to a patient an amount of a tin-annexin V effective to induce apoptosis of hyperactive microglia cells.
[0009] The tin-1 17m annexin is preferably formed from no-carrier-added tin-1 17m.
There are various methods to produce no-carrier added tin-1 17m. One such method is disclosed in Stevenson U.S. Patent 8,257,681 , the disclosure of which is hereby incorporated by reference, although other methods could be employed in the present invention. The tin-117-m is a unique radioisotope. Although it emits some gamma radiation, the primary source of the radiation is a conversion electron. The radiation from the conversion electron penetrates a set distance, 290 microns, and, therefore, does not damage cells any farther than 290 microns away from the tin atom.
[00010] The tin- 117m in turn is bonded to an annexin molecule. Annexins are a class of molecule having the ability to bind with high affinity to membrane lipids in the presence of millimolar concentrations of calcium. There are several different annexins. The term "annexin" includes native annexin purified from natural sources, such as human placenta or annexin molecules containing a native sequence produced through, for example, genetic engineering, or other means. The term annexin unless otherwise specified, includes annexms as defined below derived from or produced by any source.
[0001 1] Modified annexin is a molecule with a native sequence of molecules altered in such a way without materially altering the membrane binding affinity of the annexin. Such annexins can be produced by chemical, genetic engineering or recombinant techniques as known to those of ordinary skill in the art. The modification can include a modification of the sequence through the addition of several amino acid residues and/or an addition/deletion of amino acids at a single site of the native or genetically engineered sequence. For example, the annexin can be modified at the N- terminus by addition of amino acid residues wherein at least one of its amino acids provide an accessible sulfhydryl group. The accessible sulfhydryl group or groups may be utilized during conjugation or remain available for further conjugation. The term "modified annexin" includes annexin multimers.
[00012] Annexin multimers are a combination of two or more monomeric modified annexin molecules of which the components of the multimer may be native, or recombinant, or in any combination thereof resulting in similar or improved membrane binding affinity over the monomeric annexin. A multimer composed of up to 20 modified annexins is useful in the present invention. One example of an annexin multimer is an annexin dimer, which can be composed of two modified annexins linked by disulfide bonds between accessible cysteine groups on the modified annexins. The annexin dimer can also be produced directly as a fusion protein.
[00013] Typically a linking molecule is used to attach the tin-117m to the annexin.
One such linking molecule is l,4,7, 10-tetraazacyclododecane-l,4,7, 10-tetraacetic acid, or DOTA. Usually, aminobenzyl DOTA is used. Formation of this molecule is disclosed in U.S. Patent No. 8,283,167, the disclosure of which is hereby incorporated by reference. As discussed below, annexin V is preferably used to bind and destroy hyperactive microglia through induction of apoptosis. Annexin Al is used to repair the blood brain barrier.
[00014] Alzheimer's disease is treated by administering an effective dosage of tin- 1 17m annexin V generally linked together with DOTA. The dosage utilized in the present invention will vary depending upon the mode of administration. The tin- 1 17m annexin V in a suitable carrier, such as saline, can be administered intra- arterially, intra-spinally, including in the lumbar, or intra-cisternally, intra-vascularly, or directly into the ventricle of the brain. The more direct the path to the brain for the tin-117m, the lower the requisite dosage. Preferably, it is desirable to apply a dosage which is sufficient to provide conversion electron therapy in the brain at a hormetic dosage. Generally a much lower dosage provides hormesis, generally around 0.03 to 0.3 millicuries to each hemisphere of the brain. However, the systemic injected dosage can vary widely and can be from about 3 millicuries up to 50 millicuries, generally about 3 millicuries to about 20 millicuries or 5 to 10 millicuries.
[00015] The hyperactive microglia has exposed phosphatidyl serine to which the annexin naturally binds. This binds the tin-1 17m to the hyperactive microglia.
Because tin- 117m only has a therapeutic energy in the form of conversion electrons that travels 290 microns and that in low therapeutic doses (i.e., non-DNA fracturing doses or hormesis doses), when attached to the microglia the radiation will mainly affect interneuronal areas in the brain where aged microglia are located.
[00016] The timing of administration should be as early as possible, and can, in fact, occur prior to any clinical signs of Alzheimer's. Administration of tin-1 17m annexin V is warranted as soon as there is any indication of beta amyloid build-up, tauprotein formation, or other potential changes associated with Alzheimer's disease Because the build-up of beta amyloid precedes clinical signs of Alzheimer's by years, certainly as soon as any clinical signs of Alzheimer's are detected, the composition of the present invention should be administered. The tin-1 17m annexin V can be readmmistered. As the tin- 1 17 remains in the brain for extended periods of time, well in excess of 400 hours, one should wait at least one to two half lives before readministering the tin- 117m. The tin- 1 17m annexin can be readministered two or more times, generally for the remainder of the patient's life at 3-month to 1-year intervals. Likewise, the tin-1 17m annexin Al can b readministered at the same intervals.
Example 1
[00017] Establishing the efficacy of the present invention, 500 microcuries of tin-117m bonded to DOTA annexin V were injected into a peripheral vein of a patient as shown in the Figure. Initially, the observed dosage in brain was 1.5 microcuries, which quickly dropped off to .5 microcuries, and stabilized at between .4 and .1 microcuries over a period of over 400 hours. This demonstrates that the tin DOTA annexin crossed the blood brain barrier, localized in the brain, and remained effective in the brain over an extended period of time. The noted decrease over 400 hours would be expected due to the half-life of the tin-117m, which is 14 days. (See attached drawing.) [00018] A second therapeutic compound, tin-117m annexin Al (tin-117m
aminobenzyl DOTA annexin Al) can be administered at the same approximate dosage as the tin annexin V. The annexin Al will help repair the blood brain barrier, which is normally in disrepair in individuals with Alzheimer's, and the associated tin- 117m will induce apoptosis in aged hyperactive microglia present.
[00019] The tin- 117m- annexin Al complex can be administered at the same time as the tin- 117m-annexin V complex, but preferably, one should wait approximately one half of the half life of the tin (or 7 days), up to about two half lives (or 28 days) before administering the tin-117m-annexin Al, so that the tin- 1 17m-annexin Al does not interfere with the tin-117m annexin V crossing the blood brain barrier.
Example 2
[00020] One mCi of Sn-117m dissolved in 4 M HCI with a specific activity of 4,659 Ci/g was placed in a vial and evaporated to dryness. An aqueous solution f a bifunctional chelating agent, aminobenzyl-DOTA, was added at a 10: 1 ratio of chelant to total metal in solution. The solution was sealed and heated at 140°C for 15 minutes. The Sn-117m-DOTA chelate formed was purified by reverse phase HPLC to remove excess chelant and other impurities in the sample. The resultant purified chelate was treated with 0.2 microliters of neat thiophosgene and the excess thiophosgene was removed by three extractions with ether. This resulted in the conversion of the aniline group into an isothiocyanato group. The pH of the chelate was adjusted to abou6 then 0.37 mg of Annexin V in 0.367 microliters was added. The pH was adjusted to 9.2 with bicarbonate buffer and the solution was heated while rocking at 37°C for one 90 minutes. The contents of the vial were purified using a 10 mL gravity fed desalting column (Bio-Rad EconoPac-lODG) and 0.5 mL fractions were collected. The product peak containing Sn-117m- Annexin A-l (also referred to as lipocortin) eluted in fractions 7-10. The yield based on the Sn-117m activity was 12%.
[00021 ] In another embodiment of the present invention, the tin- 1 17m-annexin-V can be used as a diagnostic tool to determine the presence of hyperactive microglia by administering the tin-1 17m-DOTA annexin V and imaging the brain. The tin-117m emits gamma radiation, which can be detected by SPECT. Alternately, a compound such as Tc-99m annexin V can be utilized purely for diagnostic purposes. Greater than normal radiation detected in the brain is indicative of Alzheimer's disease even prior to cognitive impairment.
[00022] Thus, according to the present invention, Alzheimer's disease can be detected and/or treated at a very early stage by destroying hyperactive microglia cells before massive build-up of beta amyloid and the associated loss of brain mass and cognitive ability. The present invention allows for a method of detecting the hyperactive microglia at a very early stage, and provides a specific mode of attacking the hyperactive microglia. Because a relatively low dosage is required, a hormesis affect is achieved. Further, because of the short effective distance of the emitted radiation from the tin- 1 17m, only white matter is affected and the grey matter, or neurons of the brain, are not adversely impacted by the present therapy. This can be repeated as needed, as the compound has minimal, if any, deleterious effect. Further, the present invention provides the added benefit of being able to repair the blood brain barrier.
[00023] This has been a description of the present invention along with the preferred method of practicing the present invention. However, the invention itself should only be defined by the appended claims, WHEREIN I CLAIM:

Claims

WHAT IS CLAIMED IS:
1. A method of treating Alzheimer's disease comprising administering to an individual having Alzheimer's disease an amount of tin-117m annexin effective to induce apoptosis in aged hyperactive microglia cells in the brain.
2. The method claimed in claim 1 wherein said tin-1 17m is no-carrier-added.
3. The method claimed in claim 1 wherein said tin-1 17m annexin comprises tin- 1 17m-DOTA annexin.
4. The method claimed in claim 3 wherein said tin-117m-DOTA annexin is tin- DOTA annexin V.
5. The method claimed in claim 1 wherein said amount is from 0.03 to 50 millicuries per hemisphere if injected intra-arterially or 3.0 to 10.0 millicuries if injected intravenously.
6. The method claimed in claim 1 wherein said amount is from about 0.03 to about 1.0 millicuries when injected intrathecally by cisternal or lumbar injection.
7. The method claimed in claim 1 wherein said tin-117m annexin is administered prior to the development of clinical signs of Alzheimer's.
8. The method claimed in claim 3 wherein said tin-1 17m annexin is administered inrra-arterially.
9. The method claimed in claim 3 wherein said tin- 117m annexin is administered intra-spinally.
10. The method claims in claim 8 wherein said tin-1 17m annexin is administered into the lumbar region of the spine.
1 1. The method claimed in claim 8 wherein said tin- 1 17m annexin is administered intra-cisternally.
12. The method claimed in claim 3 wherein said tin-117m annexin is administered into a ventricle of the brain.
13. The method claimed in claim 1 further comprising administering tin-117m annexin Al .
14. The method claimed in claim 13 wherein said tin- 1 17m annexin Al is administered from 7 to 28 days after the administration of said tin-117m annexin V.
15. The method claimed in claim 13 wherein said tin- 117m annexin V is administered two or more times at 3 -month to 1-year intervals.
16. The method claimed in claim 12 wherein said tin-117m annexin Al is tin- 1 17m-DOTA-annexin Al.
17. A method of detecting hyperactive microglia comprising administering to an individual annexin V labeled with a detectable radionuclide and noninvasively detecting said radionuclide in a brain of said patient.
18. The method claimed in claim 17 wherein said radionuclide is Tc-99m.
19. The method claimed in claim 17 wherein said radionuclide is tin- 117m.
20. A composition comprising tin-117m-annexin Al .
21 The composition claimed in claim 20 comprising tin-1 17m-DOTA-annexin
Al .
PCT/US2014/038933 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide WO2014190030A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020157036396A KR20160021789A (en) 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radio nuclide
CN201480039998.4A CN105658244A (en) 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide
EP14731119.5A EP2999487A1 (en) 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide
AU2014268593A AU2014268593A1 (en) 2013-05-23 2014-05-21 Method of diagnosing and treating alzheimer's disease
US14/891,835 US10286093B2 (en) 2013-05-23 2014-05-21 Method of diagnosing and treating Alzheimer's disease
RU2015155001A RU2015155001A (en) 2013-05-23 2014-05-21 DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE WITH THE USE OF ANNEXINS LABELED WITH RADIONUCLIDE
JP2016515042A JP2016522832A (en) 2013-05-23 2014-05-21 Diagnosis and treatment of Alzheimer's disease using an annexin labeled with a radionuclide
CA2913296A CA2913296A1 (en) 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826701P 2013-05-23 2013-05-23
US61/826,701 2013-05-23

Publications (2)

Publication Number Publication Date
WO2014190030A1 true WO2014190030A1 (en) 2014-11-27
WO2014190030A8 WO2014190030A8 (en) 2015-12-10

Family

ID=50972802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/038933 WO2014190030A1 (en) 2013-05-23 2014-05-21 Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide

Country Status (9)

Country Link
US (1) US10286093B2 (en)
EP (1) EP2999487A1 (en)
JP (1) JP2016522832A (en)
KR (1) KR20160021789A (en)
CN (1) CN105658244A (en)
AU (1) AU2014268593A1 (en)
CA (1) CA2913296A1 (en)
RU (1) RU2015155001A (en)
WO (1) WO2014190030A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169289A1 (en) * 2018-03-02 2019-09-06 Neurosn, Inc. Compositions and methods of targeting and imaging aged microglia with ab peptide amino acid residues for v-domain binding of rage

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6709284B2 (en) * 2015-12-30 2020-06-10 南京中硼▲聯▼康医▲療▼科技有限公司Ｎｅｕｂｏｒｏｎ Ｍｅｄｔｅｃｈ Ｌｔｄ． Neutron capture therapy system for removing β-amyloid protein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166653A1 (en) * 2008-12-26 2010-07-01 Clear Vascular, Inc. Compositions of high specific activity sn-117m and methods of preparing the same
US20100204457A1 (en) * 2009-02-11 2010-08-12 Jaime Simon Preparation of annexin derivatives
US20110177002A1 (en) * 2008-07-18 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Cylic polyamines for binding phosphatidylserine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398118T3 (en) * 1997-04-30 2013-03-13 The Board Of Trustees Of The Leland Stanford Junior University In vivo cell death imaging procedure
EP1343529B1 (en) * 2000-12-19 2008-11-19 The Board of Regents, The University of Texas System Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US7874975B2 (en) * 2005-07-20 2011-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
JP2010524959A (en) * 2007-04-17 2010-07-22 コドマン・アンド・シャートレフ・インコーポレイテッド Nasal administration of curcumin in a helium gas bolus to treat Alzheimer's disease
CN101143897B (en) * 2007-09-27 2011-04-06 南京大学 Labeling technique for 99Tcm-His10-AnnexinV labeling compound and application of the same as developer in detecting cell apoptosis
GB0724412D0 (en) * 2007-12-14 2008-02-06 Ucl Business Plc Marker
CN103041411A (en) * 2013-01-15 2013-04-17 南京市第一医院 99Tcm-Cys-AnnexinV labeled compound with phosphatidylserine as target spot and labeling process and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110177002A1 (en) * 2008-07-18 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Cylic polyamines for binding phosphatidylserine
US20100166653A1 (en) * 2008-12-26 2010-07-01 Clear Vascular, Inc. Compositions of high specific activity sn-117m and methods of preparing the same
US8257681B2 (en) 2008-12-26 2012-09-04 Clear Vascular Inc. Compositions of high specific activity SN-117M and methods of preparing the same
US20100204457A1 (en) * 2009-02-11 2010-08-12 Jaime Simon Preparation of annexin derivatives
US8283167B2 (en) 2009-02-11 2012-10-09 Clear Vascular Inc. Preparation of annexin derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EGLE SOLITO ET AL: "Microglia Function in Alzheimer's Disease", FRONTIERS IN PHARMACOLOGY, vol. 3, 1 February 2012 (2012-02-01), XP055134645, DOI: 10.3389/fphar.2012.00014 *
LAHORTE C M M ET AL: "APOPTOSIS-DETECTING RADIOLIGANDS: CURRENT STATE OF THE ART AND FUTURE PERSPECTIVES", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER VERLAG, HEIDELBERG, DE, vol. 31, no. 6, 1 June 2004 (2004-06-01), pages 887 - 919, XP008064142, ISSN: 1619-7070, DOI: 10.1007/S00259-004-1555-4 *
NENISKYTE ET AL: "Neuronal Death Induced by Nanomolar Amyloid Is Mediated by Primary Phagocytosis of Neurons by Microglia", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 46, 18 November 2011 (2011-11-18), pages 39904 - 39913, XP055134581, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.267583 *
S. MCARTHUR ET AL: "Annexin A1: A Central Player in the Anti-Inflammatory and Neuroprotective Role of Microglia", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 10, 20 October 2010 (2010-10-20), pages 6317 - 6328, XP055134640, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001095 *
STEVENSON NIGEL ET AL: "Production and applications of very high specific activity Sn-117m and labeled chelates/molecules", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 56, no. Supplement 1, 9 May 2013 (2013-05-09), pages S40, XP008171213, ISSN: 0362-4803, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/jlcr.3057/pdf> [retrieved on 20140812], DOI: 10.1002/JLCR.3057 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169289A1 (en) * 2018-03-02 2019-09-06 Neurosn, Inc. Compositions and methods of targeting and imaging aged microglia with ab peptide amino acid residues for v-domain binding of rage

Also Published As

Publication number Publication date
AU2014268593A1 (en) 2015-12-24
EP2999487A1 (en) 2016-03-30
WO2014190030A8 (en) 2015-12-10
US20160101198A1 (en) 2016-04-14
CA2913296A1 (en) 2014-11-27
CN105658244A (en) 2016-06-08
RU2015155001A (en) 2017-06-28
KR20160021789A (en) 2016-02-26
US10286093B2 (en) 2019-05-14
JP2016522832A (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AU2005259258B2 (en) Radionuclides for medical use
ES2302698T3 (en) NEW CLINICAL PARAMETERS TO DETERMINE HEMATOLOGICAL TOXICITY BEFORE RADIOINMUNOTHERAPY.
JPH05500800A (en) Technetium/rhenium labeling method for proteins
JPH06510539A (en) Stabilizers that prevent self-radiolysis of radiolabeled peptides and proteins
CA2816070C (en) Method and kit for preparing a radiopharmaceutical
RU2741794C2 (en) Radiopharmaceutical solutions with preferred properties
KR20070106731A (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
NO332931B1 (en) Use of thorium-227 complex and complexing agent in the manufacture of a medicament, pharmaceutical composition comprising soft tissue straightening complex, soft tissue straightening complex, method of forming a complex and kit for use in the application.
US10286093B2 (en) Method of diagnosing and treating Alzheimer&#39;s disease
KR20240035757A (en) Urokinase plasminogen activator receptor-targeted radiopharmaceuticals
KR101108420B1 (en) Microwave method for preparing radiolabelled gallium complexes
KR20230134472A (en) Stable formulations for radionuclide complexes
Antczak et al. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators
JP2019123731A (en) High-purity therapeutic bone agents
CN113616818B (en) Pharmaceutical composition for targeted radiation and immunity combined treatment of tumor
KR20150010742A (en) Kit and Method for Producing a Radiopharmaceutical
Eychenne et al. Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”, Pharmaceutics, 2021, 13, 906
JPH09510454A (en) Stabilization of peptides and proteins for radiopharmaceutical use
Toegel et al. In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel “foreign carrier theory”
US20220280662A1 (en) Compositions and methods for the treatment and imaging of cancer
Odisitse et al. In Vivo bio-distribution study of 64cu (ii)-labelled copper (ii) complexes of peptides mimics in balb/c mice-development of copper based anti-inflammatory agents
RU2719418C2 (en) Composition for attaching a radioisotope to polypeptides and a method for attaching a radioisotope to polypeptides
Aneheim Poly-L Lysine based Approaches for Pretargeted Radioimmunotherapy with Astatine-211
Barreto Depleting the Latent HIV-1 Cell Population using 225Ac-labeled Anti-CD4+ Targeted Radioimmunoconjugates
AU2013261855A1 (en) Set and method for the production of a radiopharmaceutical

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14731119

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14891835

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016515042

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 242705

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2913296

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014731119

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015155001

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20157036396

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014268593

Country of ref document: AU

Date of ref document: 20140521

Kind code of ref document: A